Last reviewed · How we verify
Ferulic Acid
Ferulic Acid, marketed by Salah Awad Alanazi, is positioned in the chronic weight management segment. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the lack of reported revenue and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Ferulic Acid |
|---|---|
| Sponsor | Salah Awad Alanazi |
| Drug class | Non-Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Chronic weight management
Common side effects
Key clinical trials
- Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy (NA)
- Evaluation of Locally Applied Ferulic Acid as Adjunct to Mechanical Debridement in Treatment of Periodontitis (PHASE1, PHASE2)
- Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced (PHASE2)
- Enhanced Photoaging Reversal Efficacy and Safety of 755nm Alexandrite Picosecond Laser with Diffractive Lens Array (DLA) in Conjunction with Integrated Skin Care for Skin Quality Improvement (NA)
- Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease (PHASE2)
- Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen (PHASE1)
- Retrospective Study of ImmunoFormulation for COVID-19
- The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |